EGFR and non-small cell lung carcinoma: The AIM study, reported at the ESMO Asia 2022, enrolled advanced non-squamous NSCLC patients with uncommon EGFR mutations and indicated that Almonertinib was effective for first-line treatment of NSCLC patients with uncommon EGFR mutations other than EGFR ex20ins (13).